Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donanemab in Early Cognitive Decline with Lewy Body Features
NCT07589595Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2026
- Primary completion
- Aug 2028
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in dementia with Lewy bodies (DLB) comparing Donanemab (LY3002813) with Placebo (2 arms). Primary endpoint: Clinical Dementia Rating - Sum of Boxes at 52 weeks. Started May 2026; status: recruiting.
02
Drugs
donanemab
03
Conditions
dementia with Lewy bodies (DLB)
Beyond the preview
Go deeper on NCT07589595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07589595.